HYPOTHESIS: The severity of hearing loss (HL) associated with vestibular schwannomas (VSs) is influenced by genes expressed by the VSs. BACKGROUND: Hearing loss is the most common presenting symptoms in patients with VSs, yet its pathophysiology remains elusive. Previous studies have suggested that VSs cause HL not only by inducing degeneration of the auditory nerve by compression but also by promoting degeneration of the inner ear. This study aimed to determine whether there is a molecular basis for differences in HL associated with VSs. METHODS: Surgical specimens of VSs were collected from 13 patients and were divided into a group associated with good (word recognition >70% and pure-tone average < or =30 dB) or poor hearing. Whole-genome expression profiling of VSs was performed with the Affymetrix GeneChip Human X3P Array. The expression of select genes was validated using real-time quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. Because of a small sample size, exact nonparametric tests were used to assess the association between good versus poor hearing and specific histological features of the tumors and patient demographics. RESULTS: Using gene set enrichment analysis, the chromosomal region 3q27 was found to be significantly different between the 2 groups of tumors. This region includes peroxisomal biogenesis factor 5-like gene, which was underexpressed in VSs with poor hearing. The expression of 3 other genes from different chromosomes was significantly different between the 2 groups: RAD54B, prostate-specific membrane antigen-like, and carcinoembryonic antigen. CONCLUSION: This study identified several molecular alterations in VSs stratified by hearing. These alterations may determine the severity of HL associated with VSs and may represent potential therapeutic targets to prevent or reduce HL in theses patients.
HYPOTHESIS: The severity of hearing loss (HL) associated with vestibular schwannomas (VSs) is influenced by genes expressed by the VSs. BACKGROUND:Hearing loss is the most common presenting symptoms in patients with VSs, yet its pathophysiology remains elusive. Previous studies have suggested that VSs cause HL not only by inducing degeneration of the auditory nerve by compression but also by promoting degeneration of the inner ear. This study aimed to determine whether there is a molecular basis for differences in HL associated with VSs. METHODS: Surgical specimens of VSs were collected from 13 patients and were divided into a group associated with good (word recognition >70% and pure-tone average < or =30 dB) or poor hearing. Whole-genome expression profiling of VSs was performed with the Affymetrix GeneChip Human X3P Array. The expression of select genes was validated using real-time quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. Because of a small sample size, exact nonparametric tests were used to assess the association between good versus poor hearing and specific histological features of the tumors and patient demographics. RESULTS: Using gene set enrichment analysis, the chromosomal region 3q27 was found to be significantly different between the 2 groups of tumors. This region includes peroxisomal biogenesis factor 5-like gene, which was underexpressed in VSs with poor hearing. The expression of 3 other genes from different chromosomes was significantly different between the 2 groups: RAD54B, prostate-specific membrane antigen-like, and carcinoembryonic antigen. CONCLUSION: This study identified several molecular alterations in VSs stratified by hearing. These alterations may determine the severity of HL associated with VSs and may represent potential therapeutic targets to prevent or reduce HL in theses patients.
Authors: Andrew C Lysaght; Shyan-Yuan Kao; Joao A Paulo; Saumil N Merchant; Hanno Steen; Konstantina M Stankovic Journal: J Proteome Res Date: 2011-08-03 Impact factor: 4.466
Authors: Vitor Y R Soares; Nadia A Atai; Takeshi Fujita; Sonam Dilwali; Sarada Sivaraman; Lukas D Landegger; Fred H Hochberg; Carlos A P C Oliveira; Fayez Bahmad; Xandra O Breakefield; Konstantina M Stankovic Journal: Neuro Oncol Date: 2016-05-18 Impact factor: 12.300
Authors: Sonam Dilwali; Andrew Lysaght; Daniel Roberts; Fred G Barker; Michael J McKenna; Konstantina M Stankovic Journal: Otol Neurotol Date: 2013-06 Impact factor: 2.311
Authors: Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey Journal: Genet Res Int Date: 2012-02-20
Authors: Sonam Dilwali; Lukas D Landegger; Vitor Y R Soares; Daniel G Deschler; Konstantina M Stankovic Journal: Sci Rep Date: 2015-12-22 Impact factor: 4.379